Related Experiment Videos
[Treatment of cardiac insufficiency in ischemic heart disease]
J P Broustet1, H Douard, M Koch
1Hôpital cardiologique Haut-Lévêque, Pessac.
Insights
Cardiac failure in coronary patients is often fatal, necessitating ischemia prevention. Effective treatments target preload, afterload, and heart rate, alongside lifestyle changes for better quality of life.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Ischemic Heart Disease
Context:
- Over 30% of coronary patients die from cardiac failure outside the acute phase of myocardial infarction.
- Ischemic heart disease lacks compensatory hypertrophy, making hypertrophy a detrimental adaptation due to increased myocardial oxygen demand.
- Fibrous tissue in ischemic hearts is unresponsive to inotropic drugs, complicating treatment.
Purpose:
- To outline treatment strategies for cardiac failure in ischemic heart disease.
- To emphasize the importance of preventing or limiting ischemic episodes.
- To discuss pharmacological and interventional approaches for managing ischemia and its consequences.
Summary:
- Treatment focuses on managing ischemia through preload reduction (nitrates, molsidomine), afterload reduction (calcium antagonists, ACE inhibitors), and controlling heart rate (beta-blockers).
- Arrhythmia risk is a major concern; amiodarone, beta-blockers, and nitrates are effective antiarrhythmics.
- Revascularization benefits specific ischemic areas, but fibrosis may require surgical intervention. Comprehensive management includes weight loss, exercise rehabilitation, and limited bed rest.
Impact:
- Provides a framework for managing ischemic cardiac failure, aiming to improve patient survival and quality of life.
- Highlights the multifactorial nature of treatment, integrating pharmacological, interventional, and lifestyle modifications.
- Offers insights into optimizing therapeutic strategies by addressing specific mechanisms of ischemia and associated complications like arrhythmias and fibrosis.
Abstract:
Over 30 per cent of coronary patients die of cardiac failure excluding the acute phase of myocardial infarction. With the exception of preexisting hypertension, there is no compensatory hypertrophy in ischemic heart disease. However, hypertrophy is a costly adaptation in terms of myocardial oxygen demand and, therefore, coronary flow. Fibrous zones are unresponsive to inotropic drugs and so the treatment of cardiac failure due to ischemic heart disease consists in limiting or preventing episodes of ischemia. Each mechanism of ischemia has an appropriate treatment: the preload is reduced by trinitrin and its derivatives and by molsidomine; the after-load by calcium antagonists and angiotensin converting enzyme inhibitors; tachycardia and hypercontractile states by betablockers. The risk of arrhythmia, aggravated by many inotropic therapies, constitutes the major danger to ischemic heart failure; amiodarone, betablockers and preventive nitrate therapy are the most effective and least dangerous antiarrhythmics. Revascularisation is effective for permanently ischemic segments or for ischemia on effort but does not improve large plaques of fibrosis which sometimes require surgical ablation or plastic procedures. But these measures are incomplete if all aspects of the disease are not taken in consideration: loss of excessive body weight, exercise rehabilitation by modern techniques, limitation of bed rest at the ultimate stage of the disease allowing patients with ischemic cardiac failure a better quality of life without aggravating the prognosis.